RE:Quipt is between a rock and a hard place ..IMOAll fair points. It is difficult for them to do any deals given they have an unknown potential liability associated with the DOJ investigation. They also had a $6.5 million working capital drawdown last Q from the Change Healthcare issue. If collections normalize, cash should get back closer to $20 million, but until we see it can not be certain. The market believes this space is facing disruption and obsolescence risk so its not clear that continuing to buy DME companies is a good strategy. Best to try to find a buyer themselves. The CEO & CFO make $3.5-$4 million per year between them. The board costs another $1.5-$2 million. Audit fees, IR and public company costs are probably close to another $2 million. There may be up to $8 million or of synergies for an acquiror...Given QIPTs operating earnings are probably around $15-16 million annually (EBITA), it would be very effective for a buyer. However, the golden parachutes and rent deal for the CEO are albatrosses...